Advancements in the treatment of Alzheimer's disease: a comprehensive review

Avanços no tratamento da doença de Alzheimer: uma revisão abrangente

ABSTRACT.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. Despite being the most common cause of dementia, effective treatments have been elusive. However, recent years have witnessed significant advancements in understanding and treating Alzheimer's. Key to these advancements is the shift toward targeted therapies tailored to individual genetic and biomarker profiles, promising more effective outcomes while minimizing side effects. The integration of advanced neuroimaging techniques has revolutionized early diagnosis and disease monitoring, enabling proactive intervention strategies that may alter disease trajectories. This review provides an overview of these advancements, focusing on disease-modifying therapies, symptomatic treatments, combination therapies, lifestyle interventions, biomarker development, innovative drug delivery systems, immunotherapy, gene therapy, and neuroprotective agents.

Keywords:
Alzheimer Disease; Neuroprotective Agents; Neuroimaging; Genetic Therapy; Biomarkers

RESUMO.

A doença de Alzheimer (DA) é um transtorno neurodegenerativo progressivo caracterizado por declínio cognitivo, perda de memória e mudanças comportamentais. Apesar de ser a causa mais comum de demência, tratamentos eficazes têm sido difíceis de encontrar. No entanto, nos últimos anos, houve avanços significativos na compreensão e no tratamento da DA. Um aspecto fundamental desses avanços é a mudança para terapias direcionadas, adaptadas aos perfis genéticos e biomarcadores individuais, prometendo resultados mais eficazes e ao mesmo tempo minimizando os efeitos colaterais. A integração de técnicas avançadas de neuroimagem revolucionou o diagnóstico precoce e o monitoramento da doença, possibilitando estratégias de intervenção proativas que podem alterar as trajetórias da doença. Esta revisão oferece uma visão geral desses avanços, com foco em terapias modificadoras da doença, tratamentos sintomáticos, terapias combinadas, intervenções no estilo de vida, desenvolvimento de biomarcadores, novas vias de administração de medicamentos, imunoterapia, terapia genética e agentes neuroprotetores.

Palavras-chave:
Doença de Alzheimer; Fármacos Neuroprotetores; Neuroimagem; Terapia Genética; Biomarcadores

INTRODUCTION

Alzheimer's disease (AD) affects millions of individuals worldwide, posing substantial emotional and economic burdens on patients, families, and healthcare systems¹. Over 55 million people worldwide are living with dementia, with AD accounting for 60-70% of these cases. Each year, nearly 10 million new cases of dementia are reported, significantly impacting global health systems. In 2019, dementia incurred an estimated cost of $1.3 trillion to the global economy, with nearly 50% of these costs attributed to informal care provided by family and friends. Dementia is the seventh leading cause of death worldwide and a major cause of disability among older adults. Women are disproportionately affected, comprising 65% of dementia-related deaths and providing 70% of care hours for individuals with dementia²,³. Traditionally, treatments have been limited to managing symptoms without altering disease progression. Recent scientific progress has opened new avenues for therapeutic interventions aimed at modifying the disease course. This review synthesizes the latest research and clinical advancements in Alzheimer's treatment, highlighting their potential to transform patient outcomes (Figure 1).

Figure 1
Clinical advancements in Alzheimer's treatment.

The history of AD treatment is a convoluted narrative that intertwines medical breakthroughs, societal shifts, and persistent enigmas, each layer adding to the intricate tapestry of our understanding and management of this devastating condition⁴.

Early observations and misunderstandings

The narrative of AD began in 1906 when Alois Alzheimer, a German psychiatrist and neuropathologist, first described the pathological hallmarks of the disease — amyloid plaques and neurofibrillary tangles — during an autopsy of a patient named Auguste Deter⁵. However, the implications of his findings were not immediately understood or appreciated. At the time, dementia was largely considered a normal aspect of aging rather than a distinct pathological entity⁶. This initial period was marked by a lack of targeted treatments, as the biomedical community grappled with the fundamental nature of the disease.

The mid-20th century: emergence of neuroscientific insights

It was not until the mid-20th century that AD began to be recognized as a specific pathological condition rather than an inevitable consequence of aging. This period saw a burgeoning interest in neurobiology and the biochemical underpinnings of neurological diseases. Researchers started to explore the brain's biochemistry in greater detail, leading to early theories about the role of neurotransmitters, particularly acetylcholine, in cognitive function. However, therapeutic approaches were still rudimentary, primarily focused on symptomatic relief rather than addressing the underlying pathology⁷,⁸.

1980S: the cholinergic hypothesis and pharmacological advances

The 1980s marked a pivotal decade with the introduction of the cholinergic hypothesis, which posited that cognitive decline in AD was largely due to a deficit in acetylcholine, a neurotransmitter crucial for learning and memory. This hypothesis spurred the development of cholinesterase inhibitors, drugs designed to increase acetylcholine levels in the brain. Tacrine (Cognex), approved in 1993, was the first of these medications, followed by donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). While these drugs provided modest symptomatic relief, the search for a cure remained elusive⁵,⁹.

The amyloid cascade hypothesis and immunotherapy approaches

Parallel to the cholinergic hypothesis, the amyloid cascade hypothesis gained traction. This theory proposed that the accumulation of amyloid-beta plaques was the primary driver of Alzheimer's pathology. The late 1990s and early 2000s witnessed significant research efforts aimed at targeting amyloid-beta, including the development of immunotherapy strategies designed to clear amyloid plaques from the brain. Despite initial optimism, clinical trials for many amyloid-targeting therapies yielded disappointing results, casting doubt on the amyloid hypothesis and prompting researchers to reconsider alternative pathways⁸.

Advancements in the treatment of Alzheimer's disease

Disease-modifying therapies

All currently approved disease-modifying therapies (DMTs) for AD consist of anti-amyloid monoclonal antibodies (mAbs). The approved drugs are aducanumab (Aduhelm^®; Biogen, Cambridge, MA, USA) and lecanemab (Leqembi^®; Eisai Inc. and Biogen, Cambridge, MA, USA). Aducanumab received accelerated approval based on evidence of significant β-amyloid (Aβ) plaque reduction observed on amyloid positron emission tomography (PET), likely indicating clinical benefit. Lecanemab initially obtaining accelerated approval following a phase II study and subsequent standard approval based on data from a phase III study. Donanemab, by Eli Lilly (Indianapolis, IN, USA) is currently being assessed for regular approval based on data from phase II and III clinical trials¹⁰.

While anti-amyloid mAbs share some similarities, they also exhibit distinguishing features. From a mechanism of action (MoA) perspective, all these therapies target high molecular weight fibrillar Aβ aggregates, resulting in significant Aβ reduction observed on amyloid PET scans and associated with amyloid-related imaging abnormalities (ARIA)¹¹. The monoclonal antibodies vary in the amyloid species they target and in pharmacokinetic parameters like half-life, infusion frequency, and titration schedule¹²,¹³. Both studies included individuals with early AD, defined as mild cognitive impairment (MCI) due to AD and mild AD dementia. Notably, the definition of early AD varies across mAb trials, which could impact treatment selection for patients.

Aducanumab

Aducanumab (BIIB037; Aduhelm™) is a monoclonal auto-antibody (IgG1-mAb) that targets the N-terminal epitope made up of amino acids 3–7 of the Aβ42 peptide, showing greater affinity for fibrillar aggregates than monomers¹⁴. In June 2021, Aducanumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA), becoming the first mAb targeting Aβ and the first DMT approved for AD; shortly after, it was also approved in the United Arab Emirates (UAE). The medication is recommended for early AD patients experiencing MCI or mild dementia who show signs of brain Aβ on amyloid PET or cerebrospinal fluid (CSF) tests¹⁵. Clinical trial data indicates that the optimal dosage for aducanumab is 10 mg/kg, administered through intravenous infusions every 4 weeks¹⁵,¹⁶.

Donanemab

Donanemab (Kisunla™) is a treatment that involves administering an anti-amyloid antibody via intravenous (IV) infusion every four weeks. The FDA has granted its traditional approval for its use in treating early AD, specifically for individuals with MCI or mild dementia caused by AD, with confirmed elevated beta-amyloid in the brain.

Donanemab can postpone the advancement of Alzheimer's in its early stages, granting individuals more time to engage in daily activities and maintain independence. Patients are encouraged to consult their healthcare provider to develop a personalized Alzheimer's treatment plan, considering the benefits and risks of all authorized medications and therapies.

Lecanemab

Lecanemab (Leqembi^®) is a monoclonal antibody that targets amyloid-beta plaques. In contrast to aducanumab, lecanemab binds to protofibrils, which are a type of amyloid-beta known to be especially harmful to neurons. Clinical trials have demonstrated that lecanemab effectively decreases amyloid plaque buildup and decelerates cognitive decline in individuals with mild cognitive impairment or early AD. Ongoing research attempts to validate these results and further explore the therapeutic benefits of lecanemab. If successful, lecanemab could offer a viable alternative to aducanumab, providing patients and healthcare providers with another option for tackling AD¹⁷.

Symptom management

Cholinesterase inhibitors

Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, have been the cornerstone of symptomatic treatment for AD. These drugs work by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine, a neurotransmitter essential for learning and memory. By increasing acetylcholine levels in the brain, cholinesterase inhibitors can help improve cognitive function and delay the worsening of symptoms in mild to moderate AD. Although they do not alter the underlying disease process, these medications provide meaningful symptomatic relief for many patients¹⁸.

NMDA receptor antagonists

Memantine, an NMDA receptor antagonist, is another key medication used to manage Alzheimer's symptoms. It works by regulating the activity of glutamate, another neurotransmitter involved in learning and memory. In AD, excessive glutamate activity can lead to neuronal damage and cognitive decline¹⁰,¹⁹. Memantine helps normalize glutamate activity, thereby protecting neurons and improving cognitive function. It is often prescribed in combination with cholinesterase inhibitors to enhance overall treatment efficacy.

Combination therapies

The complexity of AD suggests that a multifaceted approach may be necessary for effective treatment. Researchers are increasingly exploring combination therapies that target different aspects of the disease. For instance, combining amyloid-targeting drugs like aducanumab with symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists may offer more comprehensive benefits. Additionally, combining drugs that target amyloid-beta with those that target tau, another protein that forms neurofibrillary tangles in AD, is an area of active investigation. The goal of combination therapies is to tackle multiple pathological processes simultaneously, potentially leading to greater improvements in cognitive function and slowing disease progression²⁰,²¹.

Lifestyle and non-pharmacological interventions

Cognitive training

Cognitive training programs involve structured mental exercises designed to improve specific cognitive functions such as memory, attention, and problem-solving. These programs can be delivered through computer-based exercises, group activities, or individualized therapy sessions. Studies have shown that regular cognitive training can help maintain or even improve cognitive abilities in individuals with AD. Moreover, cognitive training may enhance the brain's plasticity, helping it to adapt and compensate for neuronal damage²².

Diet and exercise

Diet and exercise play crucial roles in maintaining brain health and potentially reducing the risk of AD. The Mediterranean diet, rich in fruits, vegetables, whole grains, fish, and healthy fats, has been associated with a lower risk of cognitive decline and AD. Regular physical activity, including aerobic exercises like walking, swimming, and dancing, has been shown to improve cognitive function and reduce the risk of developing Alzheimer's. Exercise increases blood flow to the brain, promotes the release of neurotrophic factors that support neuron health, and helps reduce inflammation and oxidative stress. Social engagement and mental stimulation through hobbies and social activities also contribute to cognitive resilience and overall brain health²³.

Genetic and biomarker research

Genetic studies

Genetic research has identified several genes associated with an increased risk of AD. The APOE4 allele is the most well-known genetic risk factor, with individuals carrying one or two copies of this allele having a significantly higher risk of developing the disease. Understanding the genetic basis of Alzheimer's can lead to personalized medicine approaches, where treatments are tailored to an individual's genetic profile. This approach may improve treatment efficacy and reduce adverse effects²⁴,²⁵.

Biomarkers

Advancements in biomarkers have revolutionized the diagnosis and monitoring of AD. Imaging techniques, such as PET scans, can visualize amyloid-beta and tau deposits in the brain¹⁸,¹⁹,²⁶. Fluid biomarkers, including CSF and blood tests, can measure levels of amyloid-beta, tau, and other proteins associated with AD. These biomarkers allow for earlier and more accurate diagnosis, as well as the monitoring of disease progression and response to treatment. Ongoing research aims to validate and improve these biomarkers, making them more widely available and less invasive²².

Pathophysiological basis of Alzheimer's Disease biomarkers

The pathogenesis of AD is characterized by hallmark pathological features: extracellular amyloid-beta (Aβ) plaques, intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, and neuroinflammation. Biomarkers reflective of these processes serve as diagnostic and prognostic indicators.

Amyloid-Beta (Aβ) pathology biomarkers

CSF Aβ₄₂/Aβ₄₀ Ratio: The ratio of CSF Aβ₄₂ to Aβ₄₀ is a critical biomarker. A reduction in this ratio indicates Aβ plaque accumulation in the brain²⁷. Studies using PET imaging with amyloid tracers, such as florbetapir, demonstrated that patients with low CSF Aβ₄₂ levels had increased brain amyloid deposition, correlating with cognitive decline²⁸.

Amyloid PET Imaging: PET tracers, such as 11C-PiB (Pittsburgh compound B), highlight amyloid deposition in vivo, aiding in differential diagnosis of AD from other dementias²⁹.

Tau pathology biomarkers

CSF Total Tau (t-tau) and Phosphorylated Tau (p-tau): Elevated levels of t-tau indicate neuronal injury, while increased p-tau correlates with NFT pathology³⁰. High CSF p-tau levels were linked to rapid cognitive deterioration, serving as a prognostic marker in MCI patients³¹.

Tau PET Imaging: Second-generation tau PET tracers, such as flortaucipir, are increasingly utilized to map the spread of tau pathology in AD patients³².

Neurodegeneration biomarkers

Neurofilament Light Chain (NfL): Elevated levels of NfL in CSF and blood are indicative of axonal damage, reflecting neurodegeneration in AD and other neurodegenerative diseases³³.

MRI-Derived Atrophy Measures: Structural magnetic resonance imaging (MRI), detecting hippocampal atrophy, is a gold standard for assessing neurodegeneration²⁷.

Neuroinflammation biomarkers

CSF and Plasma YKL-40: Increased YKL-40 levels, a marker of astrocytosis and microglial activation, are observed in AD³⁴.

TSPO PET Imaging: PET imaging with tracers for translocator protein (TSPO) reflects microglial activation and neuroinflammation in the AD brain³⁵.

Emerging blood-based biomarkers

Advancements in ultrasensitive detection technologies, such as single-molecule array (SIMOA), have enabled the development of blood-based biomarkers, offering a less invasive and cost-effective alternative to CSF biomarkers³⁶.

Plasma Aβ₄₂/Aβ₄₀ Ratio: Reflects amyloid deposition with good correlation with amyloid PET findings³¹.

Plasma p-tau217 and p-tau181: Show promising diagnostic accuracy comparable to CSF and imaging biomarkers. Plasma p-tau217 demonstrated superior accuracy in distinguishing AD from non-AD dementias in a 2020 study³⁶.

While biomarkers revolutionize AD management, challenges remain in accessibility, cost, and standardization. Emerging technologies, such as multiomics and artificial intelligence, promise to refine biomarker discovery and application. Multiomics approaches integrating proteomics, transcriptomics, and metabolomics are identifying novel biomarker candidates, such as lipids and metabolites involved in AD pathology³⁶.

Innovative drug delivery systems

Traditional drug delivery methods often face challenges in effectively delivering therapeutic agents to the brain due to the blood-brain barrier. Innovative drug delivery systems aim to overcome these challenges. Techniques such as nasal sprays can deliver drugs directly to the brain via the olfactory pathway, bypassing the blood-brain barrier. Focused ultrasound, combined with microbubbles²³, can temporarily open the blood-brain barrier, allowing drugs to enter the brain more effectively. These advanced delivery methods have the potential to enhance the efficacy of Alzheimer's treatments by ensuring higher concentrations of therapeutic agents reach their targets in the brain²⁴.

Immunotherapy

Vaccines

Immunotherapy, including vaccines, is an emerging area of Alzheimer's research. Experimental vaccines aim to stimulate the immune system to recognize and clear amyloid-beta or tau proteins. Active immunotherapy involves injecting a patient with a modified form of the protein to elicit an immune response, while passive immunotherapy involves administering antibodies directly. Early trials of Alzheimer's vaccines have shown promise in reducing amyloid-beta levels¹⁵ and slowing cognitive decline. However, challenges such as ensuring the safety and efficacy of these vaccines need to be addressed before they can become widely available.

Gene therapy

Gene therapy offers a potential strategy for addressing the genetic underpinnings of AD. Techniques like CRISPR/Cas9 allow for precise editing of genes associated with Alzheimer's, such as APOE4²⁶,³⁷. By modifying these genes, it may be possible to reduce the risk or severity of the disease. Gene therapy also holds potential for delivering therapeutic genes that encode proteins to protect neurons or enhance brain function. While still in the experimental stages, gene therapy represents a promising frontier in Alzheimer's treatment, with the potential to halt or even reverse disease progression³⁸.

Neuroprotective agents

Neuroprotective agents are compounds that protect neurons from damage and support their function. Research into these agents is ongoing, with several showing potential in preclinical studies²⁰,²⁴,³⁹. For example, antioxidants can reduce oxidative stress, which contributes to neuronal damage in AD. Anti-inflammatory agents can mitigate neuroinflammation, another key pathological feature of Alzheimer's. Additionally, compounds that enhance mitochondrial function and energy production in neurons are being investigated. If proven effective, neuroprotective agents could complement other treatments by preserving neuronal health and function⁴⁰,⁴¹.

A list of new drugs under clinical trials, developed to treat AD, are provided in Table 1⁴²–⁴⁹.

Table 1
List of new drugs under clinical trials, developed to treat Alzheimer's disease.

Serial No.	Drug	Therapeutic target	Safety	Side effects	Reference
1	Aducanumab	Amyloid-β (Aβ) plaques	Approved by FDA but later discontinued by its manufacturer (Biogen)	Amyloid-related imaging abnormalities (ARIA), headache	42,43
2	Lecanemab	Soluble Aβ protofibrils	Approved by FDA	ARIA, infusion-related reactions, headache	42,44
3	Donanemab	Amyloid β	Approved by FDA	ARIA, infusion reactions, brain swelling	45
4	Semaglutide	GLP-1 receptor	Ongoing trials; initial results promising	Nausea, vomiting, gastrointestinal issues	42,46
5	Simufilam	Filamin A (modifies tau and Aβ42 interaction)	Phase 3 trials underway; promising early results	Headache, fatigue, gastrointestinal issues	42,43
6	Galantamine	Cholinesterase inhibitor	Widely used; well-established safety profile	Nausea, vomiting, diarrhea, weight loss	47
7	Gantenerumab	Amyloid-β (Aβ) plaques	Ongoing clinical trials	ARIA, infusion-related reactions, headache	42,48
8	Solanezumab	Amyloid-β (Aβ) monomers	Ongoing clinical trials	Infusion-related reactions, ARIA	42,43
9	Bapineuzumab	Amyloid-β (Aβ) plaques	Discontinued due to safety concerns	ARIA, vasogenic edema	42,45
10	Memantine	NMDA receptor antagonist	FDA approved; well-established safety profile	Dizziness, headache, constipation	42,43
11	Troriluzole	Glutamate modulation	Phase 2/3 trials underway	Dizziness, headache, fatigue	49
12	Tideglusib	GSK-3 inhibitor (tau phosphorylation)	Phase 2 trials showed mixed results	Nausea, diarrhea, fatigue	42
13	LMTX	Tau aggregation inhibitor	Phase 3 trials underway	Gastrointestinal issues, fatigue	43
14	ANAVEX2-73	Sigma-1 receptor agonist	Phase 2/3 trials underway	Dizziness, headache, diarrhea	42,46
15	Blarcamesine	Sigma-1 receptor and muscarinic receptor	Ongoing clinical trials	Dizziness, headache, gastrointestinal issues	42,44
16	Elamipretide	Mitochondrial dysfunction	Ongoing clinical trials	Headache, nausea, fatigue	44
17	E2814	Tau propagation inhibitor	Ongoing clinical trials	Headache, fatigue, gastrointestinal issues	42
18	ALZ-801	Amyloid oligomers	Phase 3 trials underway	Nausea, headache, fatigue	42,43
19	Edaravone	Oxidative stress	FDA approved for ALS; trials for AD underway	Bruising, gait disturbance, headache	42

• Abbreviations: FDA, Food and Drug Administration; ARIA, Amyloid-related imaging abnormalities; ALS, amyotrophic lateral sclerosis.

Future perspectives and challenges in new drug development for the treatment of Alzheimer's disease

Future perspectives

Biomarker development

The advancement of biomarkers, particularly plasma biomarkers such as p-tau217 and amyloid-beta (Aβ₄₂/₄₀) ratios, offers promising tools for early and accurate diagnosis of AD⁴⁹. These biomarkers could improve the identification of patients in the early stages, enabling timely intervention.

Advanced imaging techniques, including PET scans with new tracers for tau and amyloid, are likely to play a critical role in both diagnosis and monitoring disease progression.

Combination therapies

Future treatment strategies might involve a combination of drugs targeting different aspects of the disease, such as amyloid plaques, tau tangles, neuroinflammation, and mitochondrial dysfunction. This multifaceted approach could provide more comprehensive disease management.

Gene therapy and stem cell therapy

Gene therapy, aimed at correcting genetic mutations or modulating gene expression involved in AD pathology, represents a cutting-edge approach that holds potential for long-term solutions⁵⁰.

Stem cell therapy could offer a way to replace lost neurons and restore function, although this area is still in the early stages of research.

Personalized medicine

Advances in genomics and proteomics could enable personalized medicine approaches, tailoring treatments based on an individual's genetic profile and disease biomarkers, potentially improving efficacy and reducing side effects.

Challenges

Clinical trial design

Designing effective clinical trials for AD is challenging due to the disease's slow progression and variability in symptoms. Long trial durations and the need for large patient cohorts make these trials expensive and complex.

Regulatory hurdles

Gaining regulatory approval for new AD treatments can be difficult. The requirement for demonstrating significant clinical benefits in a disease with slow progression poses a significant hurdle.

Safety concerns

Many promising treatments have been associated with significant side effects, such as ARIA in amyloid-targeting therapies⁵¹. Balancing efficacy with safety remains a critical challenge.

Targeting amyloid-β

The amyloid cascade hypothesis has driven much of the therapeutic development for AD. Monoclonal antibodies such as aducanumab, lecanemab, and donanemab target amyloid-β plaques, which are hallmark pathological features of AD.

Aducanumab

Aducanumab showed plaque reduction in imaging studies. However, safety concerns, such as ARIA, including brain edema and microhemorrhages, were prominent. Phase III trials revealed ARIA-E in approximately 35% of patients, predominantly in ApoE4 carriers, necessitating rigorous MRI monitoring during treatment¹⁶.

Lecanemab

Similarly, lecanemab demonstrated efficacy in plaque reduction and modest cognitive improvement in the CLARITY-AD trial. However, its safety profile indicated ARIA in 21.5% of patients, with some cases resulting in discontinuation. Additionally, the risk of bleeding when combined with anticoagulants remains a critical concern for older populations⁵²,⁵³.

Donanemab

Results from the TRAILBLAZER-ALZ 2 trial suggest that donanemab can slow cognitive decline. Yet, ARIA rates were significant, affecting 37.9% of patients, with three treatment-related deaths attributed to complications of ARIA¹⁰,⁵⁴.

These findings underscore the need for pre-treatment screening for genetic risk factors like ApoE4 status, and close safety monitoring during therapy¹⁷.

Tau protein inhibitors

Abnormal tau phosphorylation and aggregation are other key pathological drivers of AD. Tau-targeting therapies, such as semorinemab and gosuranemab, are in early-phase trials⁵⁵.

Semorinemab

A Phase II trial indicated limited efficacy in slowing cognitive decline. Safety data highlighted relatively low incidences of severe adverse events compared to amyloid-targeting therapies, but long-term safety remains under investigation.

Gosuranemab

The TANGO trial was discontinued due to lack of efficacy. No significant safety signals were reported, but the modest adverse event rate suggests potential for further refinement⁵⁶.

Small molecules and repurposed drugs

Blarcamesine (ANAVEX 2-73)

A sigma-1 receptor agonist with anti-inflammatory and neuroprotective properties, blarcamesine has shown promise in Phase II trials. Common adverse events included dizziness and fatigue, which were mild and transient.

Repurposed drugs

Drugs such as metformin, pioglitazone, and sildenafil have been investigated for their neuroprotective effects. While these agents are well-tolerated in non-AD populations, their impact on cognitive outcomes and safety in AD requires further exploration.

Gene therapies and RNA-based approaches

Emerging gene therapies and RNA-targeting treatments, including antisense oligonucleotides (ASOs) like tofersen, offer exciting possibilities for modulating disease progression. These approaches are still in early stages for AD, and safety concerns, such as off-target effects and immunogenicity, remain major challenges⁵⁷.

Table 2¹¹,¹⁶,¹⁷,⁵²–⁵⁴,⁵⁸–⁶⁰ describes the brief safety profile of new treatments in AD.

Table 2
Safety of new treatments in Alzheimer's disease.

Serial No.	Drug	Adverse effects	Key risk factors for complications	References
1	Aducanumab	ARIA-E (edema), ARIA-H (hemorrhages)	APOE ε4 genotype, high amyloid burden, superficial siderosis	16
2	Lecanemab	ARIA (edema and hemorrhages), headache	APOE ε4 genotype, microhemorrhages, anticoagulant use	52,53
3	Donanemab	ARIA (27% incidence), confusion	APOE ε4 genotype, advanced amyloid plaque burden, prior microhemorrhages	54
4	Semorinemab	Cognitive worsening, inflammation	Advanced tau pathology, older age	11,17
5	Gantenerumab	ARIA, nausea, infusion reactions	APOE ε4 genotype, comorbid vascular conditions, treatment dose	58
6	Verubecestat (BACE inhibitor)	Liver toxicity, cognitive decline	Dose-dependent effects, genetic predisposition, older age	59
7	ACI-35 (Anti-Tau vaccine)	Mild inflammation, behavioral changes	Interaction with other therapies, comorbidities (e.g., vascular issues)	60

• Abbreviation: ARIA, Amyloid-related imaging abnormalities.

Understanding disease mechanisms

Despite significant progress, there is still much to learn about the underlying mechanisms of AD. This incomplete understanding complicates the development of effective therapies⁶¹.

Patient recruitment and retention

Recruiting and retaining patients for clinical trials is often difficult, especially in the early stages of the disease when individuals may not yet experience significant symptoms⁶².

Cost and accessibility

Even when new treatments are developed, ensuring they are affordable and accessible to all patients remains a significant challenge. High costs of advanced therapies may limit their widespread use.

In conclusion, the landscape of AD treatment is rapidly evolving, with significant advancements across multiple fronts. Disease-modifying therapies, innovative drug delivery systems, genetic research, and lifestyle interventions collectively offer hope for altering the course of this devastating disease. Advancements in the treatment of AD are progressing on multiple fronts, including the development of novel biomarkers, combination therapies, gene and stem cell therapies, and personalized medicine approaches.

The future of AD treatment lies in a holistic approach that combines pharmacological interventions with lifestyle modifications, cognitive therapies, and supportive care. Integrating various treatment modalities could provide more comprehensive management of the disease. Early diagnosis through advanced biomarkers allows for early intervention, which is crucial for slowing disease progression and preserving cognitive function. This underscores the importance of routine screening and monitoring in at-risk populations. Emphasizing patient-centered care, where treatment plans are tailored to individual needs and preferences, will be vital. This approach can enhance treatment adherence and overall quality of life for AD patients and their caregivers. Ongoing research into the underlying mechanisms of AD, including neuroinflammation, synaptic dysfunction, and mitochondrial impairment, will be essential for developing new therapeutic targets and strategies.

However, significant challenges remain, including the complexities of clinical trial design, regulatory hurdles, safety concerns, an incomplete understanding of disease mechanisms, patient recruitment difficulties, and issues related to cost and accessibility. Addressing these challenges will be crucial for translating scientific discoveries into effective treatments that can improve the lives of patients with AD. By addressing these challenges and continuing to explore new scientific frontiers, the future of AD treatment holds promise for more effective, safe, and personalized therapeutic options. Continued research and clinical trials are essential to translate these advancements into effective treatments, ultimately improving the quality of life for Alzheimer's patients and their families.

• This study was conducted by Department of Pharmacy Practice, East West College of Pharmacy, Bengaluru, Karnataka, India.
• Funding:
  none.

REFERENCES

• ¹ Abdullah L, Crawford F, Tsolaki M, Börjesson-Hanson A, Rikkert MO, Pasquier F, et al. The influence of baseline Alzheimer's disease severity oncognitive decline and CSF biomarkers in the NILVAD trial. Front Neurol. 2020;11:149. https://doi.org/10.3389/fneur.2020.00149
  » https://doi.org/10.3389/fneur.2020.00149
• ² Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat. 1995;8(6):429-31. https://doi.org/10.1002/ca.980080612
  » https://doi.org/10.1002/ca.980080612
• ³ World Health Organization. Global health estimates, 2022 [cited on July 3, 2024]. Available from: https://www.who.int/data/global-health-estimates
  » https://www.who.int/data/global-health-estimates
• ⁴ World Health Organization. Global status report on the public health response to dementia. 2021 [cited on July 3, 2024]. Available from: https://apps.who.int/iris/handle/10665/344701
  » https://apps.who.int/iris/handle/10665/344701
• ⁵ Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, et al. First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1 -receptor partial agonist for the treatment of dementias. Br J Clin Pharmacol. 2021;7(7):2945-55. https://doi.org/10.1111/bcp.14710
  » https://doi.org/10.1111/bcp.14710
• ⁶ Bartus RT, Dean 3^rd RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-14. https://doi.org/10.1126/science.7046051
  » https://doi.org/10.1126/science.7046051
• ⁷ Bayer TA. Pyroglutamate Aβ cascade as drug target in Alzheimer's disease. Mol Psychiatry. 2022;27(4):1880-5. https://doi.org/10.1038/s41380-021-01409-2
  » https://doi.org/10.1038/s41380-021-01409-2
• ⁸ Botchway BOA, Moore MK, Akinleye FO, Iyer IC, Fang M. Nutrition: review on the possible treatment for Alzheimer's disease. J Alzheimers Dis. 2018;61(3):867-3. https://doi.org/10.3233/JAD-170874
  » https://doi.org/10.3233/JAD-170874
• ⁹ Briggs R, Kennelly SP, O’Neill D. Drug treatments in Alzheimer's disease. Clin Med (Lond). 2016;16(3):247-53. https://doi.org/10.7861/clinmedicine.16-3-247
  » https://doi.org/10.7861/clinmedicine.16-3-247
• ¹⁰ Mintun MA, Lo AC, Evans CD, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-704. https://doi.org/10.1056/NEJMoa2100708
  » https://doi.org/10.1056/NEJMoa2100708
• ¹¹ Sperling RA, Jack Jr CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-85. https://doi.org/10.1016/j.jalz.2011.05.2351
  » https://doi.org/10.1016/j.jalz.2011.05.2351
• ¹² Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221-30. https://doi.org/10.14283/jpad.2022.34
  » https://doi.org/10.14283/jpad.2022.34
• ¹³ Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-77. https://doi.org/10.14283/jpad.2023.30
  » https://doi.org/10.14283/jpad.2023.30
• ¹⁴ Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8(1):6412. https://doi.org/10.1038/s41598-018-24501-0
  » https://doi.org/10.1038/s41598-018-24501-0
• ¹⁵ Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197-210. https://doi.org/10.14283/jpad.2022.30
  » https://doi.org/10.14283/jpad.2022.30
• ¹⁶ Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-6. https://doi.org/10.1038/nature19323
  » https://doi.org/10.1038/nature19323
• ¹⁷ Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics. Drugs. 2023;83(7):569-76. https://doi.org/10.1007/s40265-023-01858-9
  » https://doi.org/10.1007/s40265-023-01858-9
• ¹⁸ Chen C, Liao J, Xia Y, Liu X, Jones R, Haran J, et al. Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022;71(11):2233-52. https://doi.org/10.1136/gutjnl-2021-326269
  » https://doi.org/10.1136/gutjnl-2021-326269
• ¹⁹ Coimbra JR, Sobral PJ, Santos AE, Moreira PI, Salvador JAR. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease. Future Med Chem. 2019;11(24):3179-94. https://doi.org/10.4155/fmc-2019-0163
  » https://doi.org/10.4155/fmc-2019-0163
• ²⁰ Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-35. https://doi.org/10.2174/1570159X11311030006
  » https://doi.org/10.2174/1570159X11311030006
• ²¹ Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, et al. Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature. 2021;593(7858):255-60. https://doi.org/10.1038/s41586-021-03489-0
  » https://doi.org/10.1038/s41586-021-03489-0
• ²² Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018;378(4):321-30. https://doi.org/10.1056/NEJMoa1705971
  » https://doi.org/10.1056/NEJMoa1705971
• ²³ Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci. 2017;24(1):47. https://doi.org/10.1186/s12929-017-0355-7
  » https://doi.org/10.1186/s12929-017-0355-7
• ²⁴ Kellar D, Craft S. Brain insulin resistance in Alzheimer's disease andrelated disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758-66. https://doi.org/10.1016/S1474-4422(20)30231-3
  » https://doi.org/10.1016/S1474-4422(20)30231-3
• ²⁵ Kucwaj-Brysz K, Baltrukevich H, Czarnota K, Handzlik J. Chemical update on the potential for serotonin 5-HT₆ and 5-HT₇ receptor agents in the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2021;49:128275. https://doi.org/10.1016/j.bmcl.2021.128275
  » https://doi.org/10.1016/j.bmcl.2021.128275
• ²⁶ Kumar N, Gahlawat A, Kumar RN, Singh YP, Modi G, Garg P. Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors. J Biomol Struct Dyn. 2022;40(7):2878-92. https://doi.org/10.1080/07391102.2020.1844054
  » https://doi.org/10.1080/07391102.2020.1844054
• ²⁷ Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62. https://doi.org/10.1016/j.jalz.2018.02.018
  » https://doi.org/10.1016/j.jalz.2018.02.018
• ²⁸ Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-34. https://doi.org/10.1016/S1474-4422(06)70355-6
  » https://doi.org/10.1016/S1474-4422(06)70355-6
• ²⁹ Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-97. https://doi.org/10.1038/s41591-020-0762-2
  » https://doi.org/10.1038/s41591-020-0762-2
• ³⁰ Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9(3):251-61. https://doi.org/10.1016/j.jalz.2013.01.010
  » https://doi.org/10.1016/j.jalz.2013.01.010
• ³¹ Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-81. https://doi.org/10.1001/jama.2020.12134
  » https://doi.org/10.1001/jama.2020.12134
• ³² Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-24. https://doi.org/10.1016/S1474-4422(14)70252-2
  » https://doi.org/10.1016/S1474-4422(14)70252-2
• ³³ Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):71. https://doi.org/10.1186/s13195-018-0404-9
  » https://doi.org/10.1186/s13195-018-0404-9
• ³⁴ Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59. https://doi.org/10.1007/BF00308809
  » https://doi.org/10.1007/BF00308809
• ³⁵ Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379-86. https://doi.org/10.1038/s41591-020-0755-1
  » https://doi.org/10.1038/s41591-020-0755-1
• ³⁶ Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018;284(6):643-63. https://doi.org/10.1111/joim.12816
  » https://doi.org/10.1111/joim.12816
• ³⁷ Liu P, Yin YL, Wang T, Hou L, Wang XX, Wang M, et al. Ligand-induced activation of ERK1/2 signaling by constitutively active Gs-coupled 5-HT receptors. Acta Pharmacol Sin. 2019;40(9):1157-67. https://doi.org/10.1038/s41401-018-0204-6
  » https://doi.org/10.1038/s41401-018-0204-6
• ³⁸ Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, et al. Delayed-start analyses in the phase 3 solanezumab EXPEDITION3 study in mild Alzheimer's disease. J Prev Alzheimers Dis. 2018;5(1):8-14. https://doi.org/10.14283/jpad.2018.1
  » https://doi.org/10.14283/jpad.2018.1
• ³⁹ Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016;8(1):14. https://doi.org/10.1186/s13195-016-0181-2
  » https://doi.org/10.1186/s13195-016-0181-2
• ⁴⁰ Mafi JN, Leng M, Arbanas JC, Tseng CH, Damberg CL, Sarkisian C, et al. Estimated annual spending on aducanumab in the US medicare program. JAMA Health Forum. 2022;3(1):e214495. https://doi.org/10.1001/jamahealthforum.2021.4495
  » https://doi.org/10.1001/jamahealthforum.2021.4495
• ⁴¹ McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol. 2021;17(11):703-14. https://doi.org/10.1038/s41582-021-00545-1
  » https://doi.org/10.1038/s41582-021-00545-1
• ⁴² Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther. 2017;9(1):95. https://doi.org/10.1186/s13195-017-0318-y
  » https://doi.org/10.1186/s13195-017-0318-y
• ⁴³ Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553-60. https://doi.org/10.1016/j.jalz.2019.09.075
  » https://doi.org/10.1016/j.jalz.2019.09.075
• ⁴⁴ Troutwine BR, Strope TA, Franczak E, Lysaker CR, Hamid L, Mansel C, et al. Mitochondrial function and Aβ in Alzheimer's disease postmortem brain. Neurobiol Dis. 2022;171:105781. https://doi.org/10.1016/j.nbd.2022.105781
  » https://doi.org/10.1016/j.nbd.2022.105781
• ⁴⁵ Ranasinghe KG, Petersen C, Kudo K, Mizuiri D, Rankin KP, Rabinovici GD, et al. Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease. Alzheimers Dement. 2021;17(12):2009-19. https://doi.org/10.1002/alz.12349
  » https://doi.org/10.1002/alz.12349
• ⁴⁶ Recio-Barbero M, Segarra R, Zabala A, González-Fraile E, González-Pinto A, Ballesteros J. Cognitive enhancers in schizophrenia: a systematic review and meta-analysis of alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Front Psychiatry. 2021;12:631589. https://doi.org/10.3389/fpsyt.2021.631589
  » https://doi.org/10.3389/fpsyt.2021.631589
• ⁴⁷ Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017;88(18):1768-75. https://doi.org/10.1212/WNL.0000000000003904
  » https://doi.org/10.1212/WNL.0000000000003904
• ⁴⁸ Rosenbloom M, Barclay TR, Kashyap B, Hage L, O’Keefe LR, Svitak A, et al. A phase II, single-center, randomized, double-blind, placebo-controlled study ofthe safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease. Drugs Aging. 2021;38(5):407-15. https://doi.org/10.1007/s40266-021-00845-7
  » https://doi.org/10.1007/s40266-021-00845-7
• ⁴⁹ Howard R, Kales HC. New treatments for Alzheimer's disease. BMJ. 2023;382:1852. https://doi.org/10.1136/bmj.p1852
  » https://doi.org/10.1136/bmj.p1852
• ⁵⁰ Abbott A. Conquering Alzheimer's: a look at the therapies of the future. Nature. 2023;616(7955):26-8. https://doi.org/10.1038/d41586-023-00954-w
  » https://doi.org/10.1038/d41586-023-00954-w
• ⁵¹ Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. J Biomed Sci. 2023;30(1):83. https://doi.org/10.1186/s12929-023-00976-6
  » https://doi.org/10.1186/s12929-023-00976-6
• ⁵² van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. https://doi.org/10.1056/NEJMoa2212948
  » https://doi.org/10.1056/NEJMoa2212948
• ⁵³ Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, et al. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease. Nat Commun. 2023;14(1):8220. https://doi.org/10.1038/s41467-023-43933-5
  » https://doi.org/10.1038/s41467-023-43933-5
• ⁵⁴ Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-27. https://doi.org/10.1001/jama.2023.13239
  » https://doi.org/10.1001/jama.2023.13239
• ⁵⁵ Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385. https://doi.org/10.1002/trc2.12385
  » https://doi.org/10.1002/trc2.12385
• ⁵⁶ Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8(8):e72301. https://doi.org/10.1371/journal.pone.0072301
  » https://doi.org/10.1371/journal.pone.0072301
• ⁵⁷ Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging. 2021;1(6):521-34. https://doi.org/10.1038/s43587-021-00070-2
  » https://doi.org/10.1038/s43587-021-00070-2
• ⁵⁸ Roche HL. Efficacy and safety study of gantenerumab in participants with early Alzheimer's disease (AD). ClinicalTrials.gov; 2023 Apr. Report No. NCT03444870. [cited on Nov 15, 2024]. Available from: https://clinicaltrials.gov/ct2/show/NCT03444870
  » https://clinicaltrials.gov/ct2/show/NCT03444870
• ⁵⁹ Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-703. https://doi.org/10.1056/NEJMoa1706441
  » https://doi.org/10.1056/NEJMoa1706441
• ⁶⁰ Shugart J. Two new stabs at vaccinating people against pathologic tau 2022. [cited on Nov 15, 2024]. Available from: https://www.alzforum.org/news/conference-coverage/two-new-stabs-vaccinating-people-against-pathologic-tau
  » https://www.alzforum.org/news/conference-coverage/two-new-stabs-vaccinating-people-against-pathologic-tau
• ⁶¹ Digma LA, Winer JR, Greicius MD. Substantial doubt remains about the efficacy of anti-amyloid antibodies. J Alzheimers Dis. 2024;97(2):567-72. https://doi.org/10.3233/JAD-231198
  » https://doi.org/10.3233/JAD-231198
• ⁶² Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther. 2018;10(1):107. https://doi.org/10.1186/s13195-018-0431-6
  » https://doi.org/10.1186/s13195-018-0431-6

Edited by

• Editor-in-Chief:
  Sonia M. D. Brucki.

• Associate Editor:
  Elisa de Paula Resende.

Publication Dates

• Publication in this collection
  07 Apr 2025
• Date of issue
  2025

History

• Received
  09 Sept 2024
• Reviewed
  20 Nov 2024
• Accepted
  27 Nov 2024